West Virginia House Bill HB2218

West Virginia 2025 Regular Session

• Introduced: 2/12/25
• Refer: 2/12/25

Caption

Relating to the offense of adulteration or alteration of medical cannabis testing results

Summary

House Bill 2218 would create a new felony offense in West Virginia for adulterating, altering, fortifying, contaminating, or otherwise changing the tested character or purity of medical cannabis. The bill targets conduct that changes medical cannabis from its actual potency or from the potency reflected on a patient’s or caregiver’s identification card, making such conduct punishable even if it occurs in connection with testing results or product labeling. The bill establishes separate penalties for businesses and individuals. A non-natural person, such as a company or other entity, could be fined up to $2.5 million per incident and permanently lose any medical cannabis licenses. A natural person could be fined up to $100,000 per incident and face imprisonment for one to five years in a state correctional facility. The measure is aimed at protecting the integrity of the medical cannabis testing and dispensing system and deterring tampering with product potency or purity.

Impact

HB2218 would add a new section to West Virginia’s medical cannabis offenses article, creating a specific criminal prohibition and penalty structure for tampering with medical cannabis testing results or product characteristics. It would expand state law by making this conduct a felony and by authorizing substantial fines, incarceration for individuals, and permanent license revocation for licensed entities involved in the medical cannabis market. The bill would directly affect medical cannabis growers, processors, laboratories, dispensaries, license holders, and any individuals involved in handling or testing cannabis products.

Sentiment

Because there are no committee transcripts or recorded votes available, the bill’s sentiment can only be inferred from its text and purpose. The measure appears to reflect a strong enforcement-oriented approach and likely would be viewed favorably by supporters of tighter regulation, patient safety, and product integrity in the medical cannabis program. Its tone suggests concern about fraud, misrepresentation, and contamination in the cannabis supply chain rather than expansion of access or patient rights.

Contention

The main point of contention would likely be the severity of the penalties, especially the very large corporate fine and permanent revocation of medical cannabis licenses for non-natural persons. Industry participants could also object to the breadth of the prohibited conduct, including terms such as “fortifies,” “contaminates,” and “changes,” which may raise questions about proof, testing standards, and whether accidental or minor deviations could trigger felony liability. Supporters, by contrast, would likely argue that strong penalties are necessary to prevent tampering and protect patients who rely on accurate potency and purity information.